ArticleVaccine2017
Vaccine development for emerging virulent infectious diseases.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial.BMC infectious diseases · 2025Trial
- Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers.Frontiers in immunology · 2025Trial
- DNA Immunotherapy (INO-3107) Results in Long-Term Surgery Reduction in RRP.The Laryngoscope · 2025Observational
- Article
- The application of plant-exosome-like nanovesicles as improved drug delivery systems for cancer vaccines.Discover oncology · 2024Review
- Article
- Plant-Based Vaccines in Combat against Coronavirus Diseases.Vaccines · 2022Review
- Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.The New England journal of medicine · 2021Article
- A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.European journal of immunology · 2021Article
- Zika virus pathogenesis and current therapeutic advances.Pathogens and global health · 2021Review
- Zika Vaccine Development-Current Progress and Challenges for the Future.Tropical medicine and infectious disease · 2019Review
- Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases.Human vaccines & immunotherapeutics · 2019Article
- An updated roadmap for MERS-CoV research and product development: focus on diagnostics.BMJ global health · 2019Article
- The cost and challenge of vaccine development for emerging and emergent infectious diseases.The Lancet. Global health · 2018Article
- Zika Virus Vaccines: Challenges and Perspectives.Vaccines · 2018Review
- Influenza Vaccination in Type 2 Diabetes Patients: Coverage Status and Its Determinants in Southwestern Saudi Arabia.International journal of environmental research and public health · 2018Article
- Spatio-temporal coherence of dengue, chikungunya and Zika outbreaks in Merida, Mexico.PLoS neglected tropical diseases · 2018Article
- Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review.ILAR journal · 2017Review
- Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.Human vaccines & immunotherapeutics · 2017Review
- Introduction.Vaccine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreak of Zaire Ebola virus in West Africa altered the classical paradigm of vaccine development and that for emerging infectious diseases (EIDs) in general. In this paper, the precepts of vaccine discovery and advancement through pre-clinical and clinical assessment are discussed in the context of the recent Ebola virus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Zika virus outbreaks. Clinical trial design for diseases with high mortality rates and/or high morbidity in the face of a global perception of immediate need and the factors that drive design in the face of a changing epidemiology are presented. Vaccines for EIDs thus present a unique paradigm to standard development precepts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.